European Commission authorizes GSK’s HIV prevention drug

GlaxoSmithKline, GSK

European Commission authorizes GSK’s HIV prevention drug

Sept 19 (Reuters) – The European Commission has authorised GSK’s (GSK.L) HIV-focused unit ViiV Healthcare’s cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.

Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 35 kilogrammes, according to the company.

Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil.

Reporting by Eva Mathews in Bengaluru; Editing by Varun H K

Source: Reuters

/by
You might also like
GSKGSK’s gonorrhea vaccine receives FDA’s ‘fast-track’ designation
exit signAdaptimmune slashes 25% of headcount despite improved data for T-cell candidate
Bavarian NordicReutersBavarian Nordic monkeypox vaccine gets preliminary nod from EU drug regulator
Stella Kyriakides, EU Commissioner for Health and FoodEU to aggregate cancer imaging data across bloc in new project
GlaxoSmithKlineFDA adcomm clears way for GSK’s Jemperli in rectal cancer
GSK logoGSK beats expectations, shingles vaccine bolsters outlook
Novartis, GermanyEU pulls authorization of Novartis’ sickle cell disease drug
Novartis, GermanyUS CDC recommends use of new Pfizer, GSK vaccines for RSV in older adults